Stock Screener App

無料 -

インストール

0.792

2.98% -0.0243

Mira Pharmaceuticals Inc (MIRA)

概要ニュース株価時系列ディスカッション予測

Mira Pharmaceuticals Inc (MIRA) 最新ニュース

Mira Pharmaceuticals Inc (MIRA) Cash Flow - TradingKey

Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

TradingKey - TradingKey

MIRA Pharmaceuticals, Inc. Revenue Breakdown – DUS:K6S - TradingView

MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:+0.000 - TradingKey

MIRA Pharmaceuticals, Inc. Revenue Breakdown – LSX:A3EQWL - TradingView

Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

MIRA Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRA) - TradingView

Mergers & Acquisitions - Modern Healthcare

Andriy Mushak Net Worth (2026) - GuruFocus

Why Is MIRA (NASDAQ:MIRA) Non-Opioid Program in Focus? - Kalkine Media

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire

symbol__ Stock Quote Price and Forecast - CNN

MIRA Pharmaceuticals (NASDAQ:MIRA) Advances Pain Program - Kalkine Media

MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com

MIRA Pharmaceuticals announces positive preclinical results for MIRA-55 - TipRanks

Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies - Moomoo

MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 By Investing.com - Investing.com Canada

MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan

Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan

MIRA Pharmaceuticals (MIRA) Holds Near Support with Modest Gains, Resistance at $0.97 in FocusStock Surge Alerts - dars.gov.et

MIRA Q3 2025 Earnings: Positive EPS Surprise Fails to Lift SharesEarnings Revision Report - DonanımHaber

Mira reports results on optimized oral formulation of SKNY-1 - BioWorld News

Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies - Moomoo

MIRA Reports Positive Preclinical Data for SKNY-1 Program - TipRanks

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire

MIRA Pharmaceuticals (MIRA) reports promising SKNY-1 preclinical pharmacokinetic and behavioral data - Stock Titan

MIRA's obesity-and-addiction drug shows brain and liver exposure - Stock Titan

MIRA SEC FilingsMira Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

MIRA Pharmaceuticals Company Profile & Introduction - Moomoo

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 - ACCESS Newswire

MIRA Q3 2025 Earnings: EPS Beats Estimates by 26.47% as Pre-Revenue Biotech Focuses on Pipeline ProgressEPS Miss Report - dars.gov.et

What's going on with MIRA Pharma stock Tuesday? - MSN

MIRAMira Pharmaceuticals Inc Options - Finviz

MIRA Q3 2025 Earnings: Loss Narrows as EPS Surprises to the Upside, but Stock SlipsEarnings Revision Upgrade - dars.gov.et

MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt - Moomoo

MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MacPherson Edward Cloustonmoomoo - Moomoo

MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com

MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Growth Benchmark - marketscreener.com

MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell Microcap Index - marketscreener.com

MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Index - marketscreener.com

MIRA Pharmaceuticals Inc. (MIRA) Rallies 11%: Approaching Key Resistance LevelEquity Put Call - dars.gov.et

Price to earnings forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView

Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView

Price to sales forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC - Black Hills Pioneer

MIRA Pharmaceuticals, Inc. Actuals & Estimates (FWB:K6S) - TradingView

MIRA Pharmaceuticals, Inc. Actuals & Estimates (MUN:K6S) - TradingView

MIRA Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:K6S) - TradingView

K6S Forecast — Price Target — Prediction for 2027 - TradingView

MIRA Forecast — Price Target — Prediction for 2027 - TradingView

MIRA Flat at Open - Baystreet.ca

MIRA Pharmaceuticals (NASDAQ:MIRA) Reports Positive Preclinical Data for Mira-55 in Chronic Inflammatory Pain - grafa.com

Mira Pharmaceuticals reports preclinical data on pain drug candidate - Investing.com

MIRA Pharmaceuticals Advances Mira-55 for Chronic Pain Relief - GuruFocus

Mira Pharmaceuticals reports preclinical data on pain drug candidate By Investing.com - Investing.com Australia

MIRA Unveils Differentiated Preclinical Data for Mira-55 - TipRanks

MIRA’s Mira-55 eases anxiety in preclinical tests, unlike THC - Stock Titan

MIRA reports preclinical Mira-55 data showing distinct mechanism, anxiolytic activity vs THC - TradingView

PFE

$25.03

0.48%

GILD

$130.21

0.82%

AMGN

$385.16

0.64%

NVO

$47.08

8.79%

AZN

$169.66

0.98%

NVS

$156.14

1.45%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く